Background Partial reprogramming with OSK factors (Oct4, Sox2, Klf4) reverses epigenetic age and extends lifespan in aged mice, yet the benefits decline after transient expression and optimal re‑dosing intervals remain unknown【https://rejuvenatebio.com/press-releases/rejuvenate-bio-announces-gene-therapy-mediated-partial-reprogramming-extends-lifespan-and-reverses-age-related-changes-in-the-journal-cellular-reprogramming】. DNA methylation clocks provide a quantitative, tissue‑agnostic readout of epigenetic age that could serve as a feedback signal for adaptive therapy, but no published 2023‑2025 study has implemented a closed‑loop system where clock readouts directly regulate OSK expression.

Hypothesis We hypothesize that a methylation‑responsive OSK circuit—where OSK transcription is driven by a synthetic promoter whose activity increases with rising methylation at clock‑associated CpGs and falls as those sites become demethylated—will create a self‑limiting, homeostatic rejuvenation system. This adaptive OSK expression will maintain tissue epigenetic age within a youthful range, prolong functional benefits, and avoid the over‑reprogramming risks (e.g., delayed wound healing, tumorigenicity) seen with fixed‑dose regimens.

Mechanistic Rationale

1. OSK induces TET1/2‑dependent demethylation of CpG sites that are core components of the mouse Horvath‑type methylation clock【https://pmc.ncbi.nlm.nih.gov/articles/PMC7752134/】. As these sites lose methylation, the clock’s estimated epigenetic age decreases.
2. Conversely, age‑associated gain of methylation at the same CpGs recruits methyl‑binding proteins (MeCP2, MBD2) that can repress a promoter containing tandem methyl‑CpG binding domains. When methylation exceeds a preset threshold, promoter activity rises, driving OSK expression; when demethylation lowers methylation, promoter activity wanes, establishing a negative feedback loop.
3. This architecture mirrors endocrine feedback loops (e.g., corticotropin‑releasing hormone–cortisol axis), wherein the physiological output (epigenetic age) directly modulates the stimulating signal (OSK), thereby preventing overshoot.

Experimental Design

• Vector construction: Produce AAV9 carrying OSK under a minimal CMV promoter preceded by 4× methyl‑CpG binding site repeats (mCpG‑OSK). Validate in primary mouse fibroblasts that luciferase reporter activity inversely correlates with methylation at eight clock CpGs measured by targeted bisulfite pyrosequencing.
• Animal cohorts (n=15 per group, 20‑month‑old C57BL/6): (a) mCpG‑OSK (adaptive), (b) Dox‑inducible OSK (3 weeks on/1 week off) as fixed‑dose control, (c) AAV9‑empty vector.
• Longitudinal monitoring: Every 14 days, collect ~100 µL blood for bisulfite sequencing of the eight‑CpG mouse methylation clock to compute epigenetic age. Record frailty index, echocardiographic ejection fraction, and intraperitoneal glucose tolerance test at months 4, 8, and 12.
• Safety endpoint: At 14 months, perform necropsy with histopathology of liver, lung, heart, and spleen; screen for hyperplastic lesions or tumors via H&E and Ki‑67 staining.

Predictions

• Adaptive mice will maintain epigenetic age ≤ 6 months younger than chronological age throughout the study, whereas the fixed‑dose group will show progressive age‑related drift after each off‑cycle (repeated‑measures ANOVA, p < 0.001).
• Functional metrics (frailty score, EF, glucose AUC) will be significantly superior in the adaptive group at 8 and 12 months compared with fixed‑dose and controls (post‑hoc Tukey, p < 0.01).
• Tumor incidence will remain ≤ 5 % in all groups, confirming that OSK without c‑Myc does not increase oncogenic risk even with prolonged, feedback‑driven expression.

Falsifiability If the adaptive cohort fails to keep epigenetic age below the youthful threshold, shows no functional advantage over fixed dosing, or exhibits a statistically significant increase in tumorigenic lesions, the hypothesis is refuted.

Translational Implications A methylation‑guided OSK platform can be ported to mRNA or lipid‑nanoparticle delivery systems, offering a clinically translatable, self‑regulating rejuvenation therapy that adjusts dose in real time to each individual's epigenetic state.